Related Experiment Video
Updated: Feb 2, 2026
15:05
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
9.3K
Summary
The experimental drug capivasertib stabilized or shrank tumors in most patients with AKT1-mutant cancers. This AKT inhibitor shows promise for treating specific metastatic tumors.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Trials
Background:
- Metastatic cancers with AKT1 mutations represent a targetable population for therapy.
- The NCI-MATCH trial investigated targeted therapies in patients with specific genetic alterations.
Discussion:
- Capivasertib, a pan-AKT inhibitor, demonstrated anti-tumor activity in patients with AKT1-mutant metastatic disease.
- Tumor stabilization or shrinkage was observed in a majority of treated patients.
Key Insights:
- Targeting AKT signaling with capivasertib is a viable strategy for AKT1-mutant cancers.
- The U.S.-wide NCI-MATCH trial provides crucial data on the efficacy of this experimental agent.
Outlook:
- Further clinical development of capivasertib for AKT1-mutant tumors is warranted.
- This finding may inform future treatment strategies for patients with similar molecular profiles.
Related Concept Videos
01:39Mutations
94.5K
Overview
94.5K
01:35Mutations
44.5K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.5K
02:21Cancers Originate from Somatic Mutations in a Single Cell
14.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.9K
00:36Viral Mutations
39.9K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
01:09Mutation, Gene Flow, and Genetic Drift
64.3K
In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
64.3K
01:18Mutations in Microorganisms
728
Mutations are heritable changes in an organism’s genome involving alterations in the base sequence of DNA or RNA. These changes can influence cellular processes and phenotypic traits, potentially transforming the unaltered wild type into a mutant form. Such changes, termed forward mutations, are pivotal in shaping the genetic diversity of organisms.RNA viruses exhibit the highest mutation rates due to the absence of robust proofreading mechanisms during genome replication. In contrast,...
728